Versor Investments LP Sells 2,715 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Versor Investments LP lessened its position in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 49.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 2,796 shares of the company's stock after selling 2,715 shares during the period. Versor Investments LP's holdings in Inspire Medical Systems were worth $518,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Creative Planning lifted its position in shares of Inspire Medical Systems by 25.8% during the third quarter. Creative Planning now owns 3,240 shares of the company's stock valued at $684,000 after purchasing an additional 665 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Inspire Medical Systems by 153.3% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 7,800 shares of the company's stock worth $1,646,000 after acquiring an additional 4,721 shares during the period. New York State Teachers Retirement System purchased a new position in Inspire Medical Systems in the third quarter worth $1,708,000. Congress Asset Management Co. grew its stake in Inspire Medical Systems by 30.5% in the 3rd quarter. Congress Asset Management Co. now owns 5,529 shares of the company's stock valued at $1,167,000 after purchasing an additional 1,292 shares during the period. Finally, Farther Finance Advisors LLC increased its position in shares of Inspire Medical Systems by 1,158.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company's stock valued at $32,000 after purchasing an additional 139 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

Several equities analysts recently weighed in on INSP shares. Robert W. Baird reduced their price target on shares of Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating for the company in a research report on Tuesday, February 11th. Truist Financial reduced their target price on shares of Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating for the company in a research report on Tuesday, February 11th. Morgan Stanley decreased their price target on shares of Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating for the company in a research note on Tuesday, February 11th. Piper Sandler dropped their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Finally, Wells Fargo & Company decreased their target price on Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Inspire Medical Systems currently has an average rating of "Moderate Buy" and a consensus target price of $228.82.

Insider Activity

In other news, insider Randy Ban sold 25,584 shares of Inspire Medical Systems stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the completion of the sale, the insider now directly owns 7,259 shares of the company's stock, valued at approximately $1,332,026.50. The trade was a 77.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO John Rondoni sold 583 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,225 shares of company stock worth $4,806,530 in the last three months. Corporate insiders own 4.10% of the company's stock.

Inspire Medical Systems Stock Down 2.7 %

INSP traded down $4.90 during trading on Wednesday, reaching $176.18. 338,519 shares of the company were exchanged, compared to its average volume of 577,129. The company has a market cap of $5.23 billion, a price-to-earnings ratio of 101.84, a P/E/G ratio of 2.86 and a beta of 1.48. Inspire Medical Systems, Inc. has a 12-month low of $123.00 and a 12-month high of $257.40. The company's 50-day moving average is $187.46 and its two-hundred day moving average is $192.90.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. Equities analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.